SYNTONIX PHARMACEUTICALS
Syntonix discovers and develops novel, long-acting, proprietary therapeutic products using the companyโs proprietary Fc-fusion proteins and other engineered ligands which bind to specific Fc receptors. These technologies, including Syntonixโ drug delivery platform technology Transceptorโข, harness the bodyโs natural pathways for protecting antibodies against premature destruction and for transporting antibodies across cell barriers such as those in the lungs and intestines. Syntonix focus... es on using these technologies to create next generation treatments for devastating chronic diseases such as hemophilia, anemia, and autoimmune disorders. Syntonix develops selected products for specialty indications, such as hemophilia, on its own. Other products will be evaluated and commercialized through partnerships with companies with established market positions. The company is headed by an experienced management team and has focused initially on using its proprietary technology to enhance existing drugs with proven safety, efficacy, and economic return. Syntonix currently occupies a 25,000 square foot state-of-the-art laboratory facility, including a cGMP clinical manufacturing suite, in Waltham, Massachusetts.
SYNTONIX PHARMACEUTICALS
Industry:
Biotechnology Health Care
Founded:
1997-06-01
Address:
Waltham, Massachusetts, United States
Country:
United States
Website Url:
http://www.syntnx.com
Total Employee:
11+
Status:
Closed
Contact:
(781)547-6000
Email Addresses:
[email protected]
Total Funding:
35.8 M USD
Technology used in webpage:
CSC Global DNS
Current Advisors List
Current Employees Featured
Acquisitions List
Date | Company | Article | Price |
---|---|---|---|
2011-05-11 | Leeds Skin | Leeds Skin acquired by Syntonix Pharmaceuticals | 900 M GBP |
Investors List
Alta Partners
Alta Partners investment in Series B - Syntonix Pharmaceuticals
Bay City Capital
Bay City Capital investment in Series B - Syntonix Pharmaceuticals
A. M. Pappas & Associates
A. M. Pappas & Associates investment in Series B - Syntonix Pharmaceuticals
Venrock
Venrock investment in Seed Round - Syntonix Pharmaceuticals
Official Site Inspections
http://www.syntnx.com
- Host name: 165.160.13.20
- IP address: 165.160.13.20
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago